


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177 and Bond code: 40150)**

**SHARE PURCHASE PLAN FOR AN  
AGGREGATE AMOUNT OF NOT EXCEEDING HK\$1 BILLION**

This announcement is made by Sino Biopharmaceutical Limited (the “**Company**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09 and 37.47B(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors (the “**Board**”) of the Company resolved to approve a share purchase plan (the “**Share Purchase Plan**”) on 3 October 2023, pursuant to which the Company will, subject to market conditions, (1) buy back ordinary shares of the Company (the “**Shares**”) from the open market, and (2) under the restricted share award scheme adopted by the Company on 5 January 2018, instruct the trustee responsible for administering the share award scheme to purchase Shares from the open market, for an aggregate consideration of not exceeding HK\$1 billion (the “**Share Purchase Amount**”) over the next 12 months. The Board will review from time to time and determine at its sole discretion how the Share Purchase Amount will be allocated between the buyback of Shares and the purchase of award shares.

The Board has noted the recent volatility in the price of the shares of the Company and considered the value of the Company is currently grossly underestimated. The Board has decided to adopt the Share Purchase Plan in order to boost investors’ confidence and enhance shareholders’ return as soon as possible.

Since the beginning of 2023, the Company has also made accumulative Share purchases of approximately HK\$300 million. Pursuant to the general mandate granted to the Board at the Company's annual general meeting held on 15 June 2023, the Company may buy back an aggregate number of shares no more than 10% of the total issued shares of the Company as at the date of the annual general meeting. The share buyback under the Share Purchase Plan is well below such share buyback limit. Any buyback of Shares contemplated by the Company will be conducted in compliance with the Listing Rules and all other applicable laws and regulations.

The Board considers that the implementation of the Share Purchase Plan is in the best interests of the Company and its shareholders as a whole. The share purchase, in the circumstances, demonstrates the Company's confidence in its business outlook and prospects and will ultimately benefit the Company and create value for its shareholders. The Board is of the view that the Company has sufficient financial resources to implement the Share Purchase Plan and at the same time maintain a healthy financial position.

Securities holders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 3 October 2023

*As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*